KYNB · Current Report (Form 8-K) · Filed January 7, 2026

Kyntra Bio Inc — 8-K exhibit

fgen-ex3_2.htm

EX-3.2

Exhibit 3.2

FIRST AMENDMENT TO AMENDED AND RESTATED BYLAWS
OF
FIBROGEN, INC.
(to be renamed “Kyntra Bio, Inc.”)

This First Amendment to the Amended and Restated Bylaws (this “Amendment”) of FibroGen, Inc., a Delaware corporation (the “Corporation”), is adopted by the Board of Directors pursuant to the authority granted under the Corporation’s Amended and Restated Bylaws and the General Corporation Law of the State of Delaware.

Amendment to Title. The title of the Amended and Restated Bylaws is hereby amended and restated in its entirety to read as follows:

AMENDED AND RESTATED BYLAWS
OF
KYNTRA BIO, INC.

Effective Time. This Amendment shall become effective at 4:30 p.m. Eastern Time on January 7, 2026.

No Other Amendments. Except as expressly set forth in this Amendment, the Amended and Restated Bylaws shall remain unmodified and in full force and effect.


By:	/s/ John Alden
John Alden
Secretary

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer